Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
The offering is expected to close on June 10, 2024. Royalty Pharma intends to use the net proceeds from the Notes for general c...
UBS analyst Ashwani Verma downgrades Royalty Pharma (NASDAQ:RPRX) from Buy to Neutral and announces $28 price target.
Agios Pharmaceuticals sells its 15% royalty rights on U.S. net sales of Servier's vorasidenib to Royalty Pharma for $905 mi...
Unlock the latest on Royalty Pharma plc & Cytokinetics Inc.'s strategic funding collaboration for aficamten's comme...
Under the terms of ImmuNext's licensing agreement with Sanofi, ImmuNext is entitled to receive an upward tiering net royalt...
